Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

• Status: Unknown status
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Muhammad Abdulghani
• Treatments: Exenatide; Glucagon-Like Peptide 1; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Globin Zinc; Pioglitazone

Criteria

Inclusion Criteria:

• T2DM poorly controlled (HbA1c >7.5%) on metformin (>1700 mg/day) plus sulfonylurea

Exclusion Criteria:

• type 1 diabetes (T1DM) patients receiving therapy with pioglitazone, GLP-1 RA and insulin abnormal kidney, liver or heart function patients with malignancy